GnRH antagonists is one of 9 small molecule programs targeting Metastatic Neuroendocrine Prostate Cancer. It is currently in Phase 1.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
8 competitors in Metastatic Neuroendocrine Prostate Cancer
Reglan
Lu-PSMA-617
Ga-DOTA-TATE
Ga-Neob
Lu-Neob
Lu-DOTA-TATE
Gonadotropin-Releasing Hormone (gnrh) Analogues
Ga-PSMA-11
GnRH antagonists
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources